Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental brain cancer drug NRG-103 enters first human tests

NCT ID NCT07710690

Recruiting now Disease control Sponsor: Neuregen Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This early-stage trial tests an experimental drug called NRG-103 in about 24 adults with recurrent or progressive high-grade glioma, an aggressive brain cancer. The main goals are to find a safe dose and check for side effects, while also looking for early signs that the drug might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called NRG-103
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent high-grade glioma, a type of aggressive brain cancer.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, so it is far from proving effectiveness. The drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HGG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma malignant glioma pediatric high-grade glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HGG HIGH GRADE GLIOMA HIGH GRADE GLIOMA (III OR IV)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital Affiliated with Fudan University

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-••••

  • The Second Affiliated Hospital of Air Force Medical University

    NOT_YET_RECRUITING

    Xi'an, China

  • Zhongnan Hospital of Wuhan University

    RECRUITING

    Wuhan, China

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.